Loading the session
Loading the session
Loading instrument
$20.96
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:39 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
3.7M shares were sold short at the 15 Oct 2026 settlement; covering them would take 17.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: +20.7% (SPY −1.6%). 3 months: −6.2% (SPY −0.4%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SPTX, SPY · as of 4 Nov 2026
The 4 Nov 2026 close of $20.96 was 0.2% above its 50-day average ($20.92).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
2 Nov 2026 volume of 527.9K shares was 2.4× the average of the 30 sessions before it (222.5K), as the price rose 2.1%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
August 26, 2026
+12.12%July 8, 2026
+16.62%May 4, 2026
−14.31%